Regentis Biomaterials Ltd.

RGNT

Market cap $37M

The US IPO market entered the final stretch of the year with a few small listings, a wave of SPACs, and three notable deal launches on the calendar for the week ahead. With markets recovering from a recent sell-off in growth stocks, we expect several more launches from the pipeline to tee up listings for mid-December, including a potential mega IPO from medical supplies giant Medline. Several lock-ups are expiring in the week ahead, including four from companies that raised at least $50 million.

Herzliya, Israel, Dec. 05, 2025 (GLOBE NEWSWIRE) -- Regentis Biomaterials Ltd. (NYSE American: RGNT) (“Regentis”, or the “Company”), a regenerative medicine company dedicated to developing innovative tissue repair solutions that seek to restore the health and enhance the quality of life of patients, today announced the closing of its initial public offering (the “Offering”) of 1,250,000 ordinary shares (“Ordinary Shares”) at a public offering price of $8.00 per Ordinary Share, for aggregate gross proceeds of $10,000,000 before deducting underwriting discounts and offering expenses payable by the Company. In addition, the Company granted the underwriters a 45-day option to purchase up to an additional 187,500 Ordinary Shares to cover over-allotments, if any.